Plain-English translation of NCT07050043 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether combining a low dose of nivolumab (an immunotherapy medication that helps your immune system fight cancer) with standard chemotherapy is more effective than chemotherapy alone for people with advanced non-small cell lung cancer. About half of participants will receive the medication plus chemotherapy, while the other half will receive chemotherapy alone. Researchers want to see whether adding this treatment helps people live longer and respond better to their cancer care.
Standard chemotherapy alone helps some patients with advanced lung cancer, but many still don't survive as long as doctors hope. This trial is testing whether this medication, which works by boosting the immune system, can improve outcomes when combined with chemotherapy—potentially offering patients a better chance of response and survival.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to one of two groups: either low-dose nivolumab combined with standard chemotherapy, or standard chemotherapy alone. Your treatment will consist of 4 to 6 cycles of chemotherapy (usually given over several months), and if in the combination group, weekly doses of the medication. You will need to visit the clinic regularly for treatment, blood tests, and scans to monitor how your cancer is responding. The trial also requires a tumor tissue sample to confirm your cancer type and PD-L1 status before you start.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Malaysia